Clinical Trials Logo

Gastroparesis clinical trials

View clinical trials related to Gastroparesis.

Filter by:

NCT ID: NCT00761254 Terminated - Nausea Clinical Trials

Domperidone for Relief of Gastrointestinal Disorders

Start date: August 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.

NCT ID: NCT00760461 Terminated - Gastroparesis Clinical Trials

Domperidone in Refractory Gastroparesis

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.

NCT ID: NCT00733551 Completed - Gastroparesis Clinical Trials

Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.

Start date: September 23, 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.

NCT ID: NCT00682877 Completed - Gastroparesis Clinical Trials

A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old

GETOver65
Start date: July 2007
Phase: N/A
Study type: Observational

The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying scintigraphy for subjects 65 years of age and older.

NCT ID: NCT00639808 Completed - Diabetes Mellitus Clinical Trials

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.

NCT ID: NCT00622804 Withdrawn - Stomach Cancer Clinical Trials

Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the degree of bile reflux and gastric stasis according the reconstruction methods after distal subtotal gastrectomy for gastric cancer, and to find out the proper method. We collect ninety patients who undergo distal gastrectomy for gastric cancers for this study from 5 institutions and randomly divide into 3 groups according to reconstruction methods: 1) Billroth-II (B-II), 2) Roux en Y gastrojejunostomy (RY-GJ) and 3) uncut Roux en Y gastrojejunostomy (uncut RY-GJ).

NCT ID: NCT00612014 Completed - Diabetes Mellitus Clinical Trials

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.

NCT ID: NCT00595621 Completed - Gastric Stasis Clinical Trials

Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis

Start date: February 2006
Phase: N/A
Study type: Interventional

Investigate the safety and efficacy of multi-channel gastric electrical stimulation in the treatment of patients with severe diabetic gastroparesis refractory to standard therapy.

NCT ID: NCT00568373 Withdrawn - Gastroparesis Clinical Trials

Gastric Pacemaker Implantation for Gastroparesis

HUD
Start date: June 2007
Phase: N/A
Study type: Interventional

Gastric pacemakers and/or temporary gastric stimulators will be implanted in eligible patients.

NCT ID: NCT00562848 Completed - Gastroparesis Clinical Trials

A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040

Start date: September 10, 2007
Phase: Phase 1
Study type: Interventional

Motilin is a peptide whose action is controlled by motilin receptors located in the gut. Action of Motilin at motilin receptors increases the gastric emptying rate (rate of emptying of food and fluid from the stomach). Compounds which stimulate motilin receptors therefore provide a potential approach to the treatment of a range of clinical conditions where delayed gastric emptying may contribute to symptoms, such as enteral feeding intolerance (post-operative or intensive care patients), gastroparesis, diabetic gastroparesis, and functional dyspepsia. This study is the First Time In Human study for the motilin receptor agonist, GSK962040.